Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003379 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00003379 is a Phase 1 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 40 participants.
The verdict
NCT00003379, a Phase 1 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy to the pelvis plus paclitaxel and cisplatin in treating patients who have cervical cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- RADIATION brachytherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003379
The ClinicalTrials.gov registry entry for NCT00003379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00003379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003379 about?
NCT00003379 is a clinical study titled "Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop...
What is the current status of trial NCT00003379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1999-11.
What interventions are being tested in trial NCT00003379?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT00003379?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.